TM4SF4 and LRRK2 Are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis.

Cancer Res Treat · 2021 · PMC7812009 · PMID 32972043

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In outlier samples, CDK4 in lung cancer, and CDK12 , and ERBB2 in breast cancer showed a trend to have higher DNA copy numbers and DNA hypomethylation levels than in others.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.